Skip to content
lifestyle.smarttalksuccess.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly declares second-quarter 2026 dividend
May 6, 2026
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
May 5, 2026
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
May 5, 2026
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
May 4, 2026
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
May 4, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
May 3, 2026
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
May 2, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
May 1, 2026
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
April 30, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
April 29, 2026
←
Previous Page
1
2
3
4
5
6
Next Page
→